This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Q2 FY27 revenue and net profit surge; operating cash flow stays negative
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter to 30 September 2026: revenue was Rs 581.98 lakh versus Rs 157.63 lakh a year earlier, up 269%, while net profit was Rs 72.53 lakh versus Rs 6.75 lakh, up 974%. Standalone half-year operating cash flow was negative Rs 58.28 lakh. The auditor highlighted Rs 574.16 lakh of old receivables with no loss provision and Rs 431.42 lakh of advances without confirmations. The board proposed up to Rs 3 crore of warrants, pending approvals.
Revenue and profit growth may support sentiment, but negative cash flow, collection risks and dilution from Rs 3 crore equity warrants may weigh.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹5.82 Cr | ₹1.58 Cr | +269.2% |
| Operating profit | ₹0.95 Cr | ₹0.03 Cr | +2,836.0% |
| Profit after tax | ₹0.73 Cr | ₹0.07 Cr | +974.5% |
| EBITDA margin | 17.8% | 2.1% | +15.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.